Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: The investigation of Mitogen-Activated Protein kinase Phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging

Figure 5

Non-invasive bioluminesence monitoring of NSCLC tumour suppression by either MKP-1 over-expression or rosiglitazone treatement. (A) Representative bioluminescence images of SCID mice injected with either control H441GL cells (H441GL), MKP-1 over-expressing H441GL (H441GL/MKP-1) or control H441GL-inoculated mice receiving daily oral rosiglitazone (100 mg/kg/d) treatment (ROSI-H441GL) The intensity of bioluminescent signals increased in both control and ROSI-treated groups but not the mice inoculated with H441GL/MKP-1, over the 14-day observation period The intensity of bioluminescent signals reflects the increase in tumour burden (B) Metastatic ability was tabulated based on bioluminescence analysis Control H441GL mice showed the highest lung-to-hind leg metastasis rate (625%) followed by ROSI-H441GL (25%) and H441GL/MKP-1 animals (125%) (C) Kaplan-Meier plot indicated that H441GL/MKP-1 animals had the best survival rate among the three groups, ROSI-H441GL group being the modest (60%) and the control H441GL animals the worst (25%) The insert table depicts the percentage of lung-to-bone metastases obtained from three groups.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us